← Leaderboards
Rosa G Hendler
Yale University
$103,605
Attributed
$103,605
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$103,605 · 3
By mechanism
M01$103,605 · 3
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- Carlos M Grilo$23,768,687
- Gerald I Shulman$43,949,903
- Janice Jin Hwang$5,677,315
- Melinda L Irwin$13,917,828
- Robert Stanley Sherwin$134,887,212
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectDrug Screening /EvaluationHypoglycemic AgentsDrug Adverse EffectOutcomes ResearchLipid MetabolismHuman Therapy EvaluationThiazolesNoninsulin Dependent Diabetes MellitusLongitudinal Human StudyDiabetes Mellitus TherapyRacial /Ethnic DifferenceWeight ControlWeight LossAfrican AmericanWomen'S HealthBasal MetabolismCarbohydrate MetabolismCaucasian AmericanFemaleGlucose TransportGlycogenolysisInsulin Dependent Diabetes Mellitus
Grant awards (4)
SIX MONTH PHASE II TRIAL OF PIOGLITAZONE GROUP IN NIDDM PATIENTS$0
M01 · FY2001 · RR
METABOLIC RATE AND PROTEIN, CARBOHYDRATE AND LIPID METABOLISM IN OBESITY$34,535
M01 · FY2000 · RR
SIX MONTH PHASE II TRIAL OF PIOGLITAZONE GROUP IN NIDDM PATIENTS$34,535
M01 · FY2000 · RR
EFFECTS OF ACARBOSE IN GLYCEMIC &LIPID CONTROL IN IDDM PATIENTS (TYP$34,535
M01 · FY2000 · RR